Nkarta to Present NKX019 Phase 1 Dose Escalation Data at European Hematology Association 2023 Congress and 17th International Conference on Malignant Lymphoma
11 Mayo 2023 - 3:01PM
Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing
engineered natural killer (NK) cell therapies, today announced that
it will present preliminary data from its Phase 1 dose escalation
clinical trial of NKX019 at two upcoming scientific conferences in
June 2023: the European Hematology Association (EHA) 2023 Hybrid
Congress and the 17th International Conference on Malignant
Lymphoma (17-ICML). NKX019 is an allogeneic, off-the-shelf cell
therapy candidate comprising NK cells derived from healthy donors
and engineered to target the B-cell antigen CD19.
The purpose of the presentations is to ensure that
clinical investigators and the broader clinical community have the
opportunity to assess the NKX019 clinical data from the November
2022 data cut-off in a peer-reviewed format. These data were
previously disclosed at a company event in December 2022. Nkarta
continues to plan to present an update to these data later in
2023.
European Hematology Association 2023 Hybrid
CongressOral Presentation: First in Human Data of NKX019,
an Allogeneic CAR NK for the Treatment of Relapsed/Refractory (R/R)
B-Cell MalignanciesJune 10, 2023Session s437 4:30 p.m. - 5:45 p.m.
CESTPresentation S261Abstracts are available on the EHA
website.
17th
International Conference on Malignant Lymphoma
Encore Poster Presentation: First in Human Data of NKX019, an
Allogeneic CAR NK for the Treatment of Relapsed/Refractory (R/R)
B-Cell MalignanciesJune 14 - June 16, 2023Abstract 389Abstract
titles are available on the 17-ICML website. Abstracts are expected
to be available on the ICML website on June 9, 2023 at 5:59 p.m.
ET.
The presentations will be made available
electronically on the Nkarta website following their delivery at
the scheduled scientific sessions.
About NKX019NKX019 is an
allogeneic, cryopreserved, off-the-shelf cancer immunotherapy
candidate that uses natural killer (NK) cells derived from the
peripheral blood of healthy adult donors. It is engineered with a
humanized CD19-directed CAR for enhanced tumor cell targeting and a
proprietary, membrane-bound form of interleukin-15 (IL-15) for
greater persistence and activity without exogenous cytokine
support. CD19 is a biomarker for normal and malignant B cells, and
it is a validated target for B cell cancer therapies. To learn more
about the NKX019 clinical trial in adults with advanced B cell
malignancies, please visit ClinicalTrials.gov.
About NkartaNkarta is a
clinical-stage biotechnology company advancing the development of
allogeneic, off-the-shelf natural killer (NK) cell therapies. By
combining its cell expansion and cryopreservation platform with
proprietary cell engineering technologies and CRISPR-based genome
engineering capabilities, Nkarta is building a pipeline of future
cell therapies engineered for deep anti-tumor activity and intended
for broad access in the outpatient treatment setting. For more
information, please visit the company’s website at
www.nkartatx.com.
Cautionary Note on Forward-Looking
Statements Statements contained in this press release
regarding matters that are not historical facts are
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995, as amended. Words such as
"anticipates," "believes," "expects," "intends," “plans,”
“potential,” "projects,” “would” and "future" or similar
expressions are intended to identify forward-looking statements.
Examples of these forward-looking statements include, but are not
limited to, statements concerning Nkarta’s expectations regarding
any or all of the following: the timing of release of additional
NKX019 clinical trial data and the nature of the data to be
released. Because such statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. These
risks and uncertainties include, among others: Nkarta’s limited
operating history and historical losses; Nkarta’s lack of any
products approved for sale and its ability to achieve
profitability; the risk that the results of preclinical studies and
early-stage clinical trials may not be predictive of future
results; Nkarta’s ability to raise additional funding to complete
the development and any commercialization of its product
candidates; Nkarta’s dependence on the clinical success of its two
lead product candidates, NKX101 and NKX019; that Nkarta may be
delayed in initiating, enrolling or completing any clinical trials;
competition from third parties that are developing products for
similar uses; Nkarta’s ability to obtain, maintain and protect its
intellectual property; Nkarta’s dependence on third parties in
connection with manufacturing, clinical trials and pre-clinical
studies; the complexity of the manufacturing process for CAR NK
cell therapies; the availability of components and supplies
necessary for the conduct of our clinical trials; and risks
relating to the impact on our business of the COVID-19 pandemic or
similar public health crises.
These and other risks are described more fully in
Nkarta’s filings with the Securities and Exchange Commission
(“SEC”), including the “Risk Factors” section of Nkarta’s Annual
Report on Form 10-K for the quarter and year ended December 31,
2022, filed with the SEC on March 16, 2023, and Nkarta’s other
documents subsequently filed with or furnished to the SEC. All
forward-looking statements contained in this press release speak
only as of the date on which they were made. Except to the extent
required by law, Nkarta undertakes no obligation to update such
statements to reflect events that occur or circumstances that exist
after the date on which they were made.
Nkarta Media/Investor Contact:Greg
MannNkarta, Inc.gmann@nkartatx.com
Nkarta (NASDAQ:NKTX)
Gráfica de Acción Histórica
De Jul 2024 a Ago 2024
Nkarta (NASDAQ:NKTX)
Gráfica de Acción Histórica
De Ago 2023 a Ago 2024